The president's latest announcement sent ripples through financial markets, with investors bracing for volatility
President Donald Trump escalated trade tensions Tuesday by threatening to impose new 25% tariffs on automobiles, pharmaceuticals, and semiconductors, heightening concerns over a potential trade war. The announcement has sent ripples through financial markets, with investors bracing for potential volatility.
Let’s take a closer look at how stocks are reacting to the news.
Elon Musk-led Tesla $TSLA (TSLA) saw its stock rise 2.2% to $363 on Wednesday, making it one of the top-performing stocks on the Nasdaq $NDAQ. Ford $F (F), on the other hand, was up less than 1%.
One key difference between Tesla and Ford is their production strategies. While Tesla manufactures its vehicles domestically, Ford imports approximately 20% of the cars it sells in the U.S. The new tariffs are expected to drive up costs, a concern highlighted by Ford CEO Jim Farley, who recently remarked that Trump’s tariffs are causing “a lot of cost and a lot of chaos.”
Foreign automakers also felt the impact of the tariff threat. The stock prices of Germany-based Volkswagen (VWAGY) and Japan’s Nissan (NSANF) were down more than 3% and 2%, respectively.
The escalating chip war between the U.S. and China, compounded by a series of retaliatory tariffs, is poised to have far-reaching consequences for the global AI industry.
Major AI stocks in the U.S., including Nvidia $NVDA (NVDA), Super Micro Computer (SMCI), and Advanced Micro Devices (AMD $AMD), continued to climb Wednesday. However, Taiwan Semiconductor Manufacturing (TSM) saw its stock dip following President Trump’s latest remarks.
The tariff announcement had a positive impact on U.S.-listed pharmaceutical stocks on Wednesday, with companies like Eli Lilly $LLY (LLY), Novartis (NVS), Novo Nordisk (NVO), Pfizer $PFE (PFE), and Moderna $MRNA (MRNA) all trading in the green.
However, the news dealt a severe blow to pharmaceutical companies based in India, where major players like Sun Pharma and Dr. Reddy’s Laboratories saw significant declines.
